£30m boost for the DGH

Darren Grayson Chief Executive Officer East Sussex Healthcare NHS Trust. May 17th 2011 E20061M
Darren Grayson Chief Executive Officer East Sussex Healthcare NHS Trust. May 17th 2011 E20061M

Plans have been approved to invest £30 million to go towards the redevelopment of the DGH and the Conquest Hospital.

The trust board has backed the plans for East Sussex Healthcare NHS Trust’s main acute hospitals as part of the implementation of the first phase of the ‘Shaping our Future’ Clinical Strategy.

A capital investment of £30 million to implement the clinical strategy has been agreed as part of a Full Business Case which is now subject to final ratification by the Trust Development Authority.

The investment is split between the two hospitals with £15.3 going to the Hastings hospital and £14.7 million to the DGH.

A decision from the Trust Development Authority is anticipated in spring next year.

Darren Grayson, chief executive of the trust, said, “The approval of plans for this significant investment is the foundation stone to improving the quality of services in both hospitals.

“The implementation of our clinical strategy offers us an important opportunity to ensure that we are able to deliver sustainable heath care services for local people in the future.

“It will ensure we are able to respond to national and local requirements to improve patient safety, patient outcomes and service quality as well as meeting performance standards.

“The capital investment, subject to approval by the Trust Development Authority, will enable us to redesign areas of our hospitals and support the required building work to fully develop our estate to meet our future strategic needs and bring services in East Sussex into the modern era.”

The plans contained within the approved full business case include specialist stroke and cardiology facilities at the DGH, as well as the redesigning and development of A&E, medical assessment unit and day surgery and reprovision of an expanded Pevensey ward and day unit for cancer and haematology patients.